Pharmacovigilance Services and Solutions segmentation by application reveals five primary clusters that collectively drive market revenue. Adverse Event Reporting accounts for roughly 30 % of spend, reflecting the mandatory capture, triage, and submission of individual case safety reports to regulatory bodies; its scale is anchored by the volume of marketed products and post‑marketing obligations. Signal Detection & Management represents about 25 % and encompasses systematic data mining, disproportionality analysis, and periodic safety update reporting, activities that generate high‑value insight and therefore command premium pricing. Risk Management Planning contributes near 20 %, covering the design and execution of risk‑minimization measures, such as REMS and post‑authorisation safety studies, where complexity and regulatory scrutiny raise service fees. Regulatory Compliance & Submission holds 15 % of the market, involving dossier preparation, electronic submission, and audit support; its contribution is proportional to the frequency of new drug approvals and label changes. Finally, Safety Data Management captures the remaining 10 %, providing database architecture, data cleaning, and integration services that underpin all other functions. The proportional distribution is illustrated in the accompanying pie‑chart.